Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-08-25

Clinical Trial Update: Gevokizumab for Active Scleritis [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of Gevokizumab for active scleritis has completed, and its results were posted in August 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Gevokizumab (gevokizumab)

Snippet

Sponsor: National Eye Institute (NEI) | Conditions: Scleritis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2015-08-25